Skip to main
TRVI
TRVI logo

TRVI Stock Forecast & Price Target

TRVI Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Trevi Therapeutics Inc is advancing its clinical-stage candidate Haduvio, aimed at addressing chronic cough in adults with idiopathic pulmonary fibrosis and prurigo nodularis, which positions the company in a niche market with significant unmet medical needs. The company's progress in clinical trials will be instrumental in determining its future valuation and potential for success, reflecting the critical nature of data in biotech stock performance. Additionally, maintaining adequate capital is essential for Trevi to continue its operational and developmental plans effectively, which further underscores the importance of financial health in facilitating the advancement of its promising therapies.

Bears say

Trevi Therapeutics faces significant risks related to its clinical trials for Haduvio, as failure to meet trial endpoints or the emergence of safety signals could lead to asset impairment and a decrease in stock value. The company is also operating in highly competitive therapeutic areas, which may hinder its ability to effectively market its products and generate returns on investments. Additionally, Trevi’s anticipated need for capital raises before achieving profitability adds further financial strain and uncertainty to its long-term viability.

TRVI has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Trevi Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Trevi Therapeutics Inc (TRVI) Forecast

Analysts have given TRVI a Strong Buy based on their latest research and market trends.

According to 9 analysts, TRVI has a Strong Buy consensus rating as of Oct 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Trevi Therapeutics Inc (TRVI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.